Leerink raised the firm’s price target on Cytokinetics (CYTK) to $83 from $73 and keeps an Outperform rating on the shares. The firm is updating its model to reflect the Food and Drug Administration approval of Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy and its incrementally more positive view on Myqorzo’s commercial outlook following the differentiated label and Risk Evaluation and Mitigation Strategy profile.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $71 from $65 at Morgan Stanley
- Cytokinetics price target raised to $64 from $63 at BofA
- Cytokinetics price target raised to $84 from $70 at Truist
- Cytokinetics price target raised to $83 from $73 at Leerink
- Cytokinetics price target raised to $95 from $87 at RBC Capital